Advertisement
UK markets close in 4 hours 27 minutes
  • FTSE 100

    8,093.71
    +53.33 (+0.66%)
     
  • FTSE 250

    19,694.49
    -24.88 (-0.13%)
     
  • AIM

    754.94
    +0.25 (+0.03%)
     
  • GBP/EUR

    1.1662
    +0.0017 (+0.15%)
     
  • GBP/USD

    1.2506
    +0.0043 (+0.35%)
     
  • Bitcoin GBP

    50,790.98
    -2,341.43 (-4.41%)
     
  • CMC Crypto 200

    1,351.92
    -30.66 (-2.22%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CRUDE OIL

    82.91
    +0.10 (+0.12%)
     
  • GOLD FUTURES

    2,339.80
    +1.40 (+0.06%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    17,977.98
    -110.72 (-0.61%)
     
  • CAC 40

    8,029.50
    -62.36 (-0.77%)
     

Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio

Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio

In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $312.5 million compared to $291 million in 4Q16. In fiscal 2017, Xyrem reported revenues of $1.2 billion compared to $1.1 billion in 2016, which reflected a 7% growth on a YoY basis. Xyrem is used for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy.